These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 16675710)
1. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Kralovics R; Teo SS; Li S; Theocharides A; Buser AS; Tichelli A; Skoda RC Blood; 2006 Aug; 108(4):1377-80. PubMed ID: 16675710 [TBL] [Abstract][Full Text] [Related]
2. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. Colaizzo D; Amitrano L; Tiscia GL; Scenna G; Grandone E; Guardascione MA; Brancaccio V; Margaglione M J Thromb Haemost; 2007 Jan; 5(1):55-61. PubMed ID: 17059429 [TBL] [Abstract][Full Text] [Related]
3. Platelet and coagulation activation markers in myeloproliferative diseases: relationships with JAK2 V6I7 F status, clonality, and antiphospholipid antibodies. Robertson B; Urquhart C; Ford I; Townend J; Watson HG; Vickers MA; Greaves M J Thromb Haemost; 2007 Aug; 5(8):1679-85. PubMed ID: 17596137 [TBL] [Abstract][Full Text] [Related]
4. Oncogenic mechanisms in myeloproliferative disorders. Delhommeau F; Pisani DF; James C; Casadevall N; Constantinescu S; Vainchenker W Cell Mol Life Sci; 2006 Dec; 63(24):2939-53. PubMed ID: 17131059 [TBL] [Abstract][Full Text] [Related]
5. Life histories of myeloproliferative neoplasms inferred from phylogenies. Williams N; Lee J; Mitchell E; Moore L; Baxter EJ; Hewinson J; Dawson KJ; Menzies A; Godfrey AL; Green AR; Campbell PJ; Nangalia J Nature; 2022 Feb; 602(7895):162-168. PubMed ID: 35058638 [TBL] [Abstract][Full Text] [Related]
8. Serum Has Higher Proportion of Janus Kinase 2 V617F Mutation Compared to Paired EDTA-Whole Blood Sample: A Model for Somatic Mutation Quantification Using qPCR and the 2 Barra GB; Santa Rita TH; Almeida ALSC; Jácomo RH; Nery LFA Diagnostics (Basel); 2020 Mar; 10(3):. PubMed ID: 32178286 [TBL] [Abstract][Full Text] [Related]
9. Molecular analysis of V617F mutation in Janus kinase 2 gene of breast cancer patients. Karim S; Malik IR; Nazeer Q; Zaheer A; Farooq M; Mahmood N; Malik A; Asif M; Mehmood A; Khan AR; Jabbar A; Arshad M; Yousafi Q; Hussain A; Mirza Z; Iqbal MA; Rasool M Saudi J Biol Sci; 2019 Sep; 26(6):1123-1128. PubMed ID: 31516339 [TBL] [Abstract][Full Text] [Related]
10. Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk. Kishtagari A; Khan MAW; Li Y; Vlasschaert C; Marneni N; Silver AJ; von Beck K; Spaulding T; Stockton S; Snider C; Sochacki A; Dorand D; Mack TM; Ferrell PB; Xu Y; Bejan CA; Savona MR; Bick AG Blood Cancer J; 2024 Jan; 14(1):6. PubMed ID: 38225345 [TBL] [Abstract][Full Text] [Related]
11. A New Murine Model of Clonal Hematopoiesis Investigates Patel AP; Natarajan P JACC Basic Transl Sci; 2019 Oct; 4(6):698-700. PubMed ID: 31713537 [TBL] [Abstract][Full Text] [Related]
18. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Schaub FX; Looser R; Li S; Hao-Shen H; Lehmann T; Tichelli A; Skoda RC Blood; 2010 Mar; 115(10):2003-7. PubMed ID: 20061559 [TBL] [Abstract][Full Text] [Related]
19. SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Lasho TL; Jimma T; Finke CM; Patnaik M; Hanson CA; Ketterling RP; Pardanani A; Tefferi A Blood; 2012 Nov; 120(20):4168-71. PubMed ID: 22968464 [TBL] [Abstract][Full Text] [Related]